Physician profile
Cosmin Dascalu
NPI 1083917835
$25,674.99
in general payments reported to CMS, 2019-2025
51 companies · $4,566 in 2025
The $4,566 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,571 · 2020: $2,523 · 2021: $2,768 · 2022: $3,935 · 2023: $3,673 · 2024: $3,639 · 2025: $4,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,547.39 |
| Education | $329.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,175.37 | 2019-2025 | Evenity, Tavneos, Krystexxa |
| Abbvie INC. | $2,547.18 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,530.31 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,949.24 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $1,526.38 | 2019-2023 | Krystexxa |
| Pfizer INC. | $1,043.79 | 2019-2025 | |
| Lilly USA, LLC | $959.26 | 2019-2024 | Taltz, Zepbound, Omvoh |
| Pacira Therapeutics, INC. | $951.18 | 2019-2021 | |
| Radius Health, INC. | $835.54 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $727.06 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $706.81 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $687.85 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.91 | 2019-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $609.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $562.80 | 2021-2025 | Saphnelo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cosmin Dascalu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.